Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. (4th November 2022)

• Record Type: Journal Article
• Authors: Ray, Kausik K; Kallend, David; Leiter, Lawrence A; Raal, Frederick J; Koenig, Wolfgang; Jaros, Mark J; Schwartz, Gregory G; Landmesser, Ulf; Garcia Conde, Lorena; Wright, R Scott
• Is Part Of: European heart journal. Volume 43:Number 48(2022)
• Page Start: 5047
• Page End: 5057
• Publication Date: 2022-11-04
• Subjects: ASCVD -- Inclisiran -- Hypercholesterolaemia -- Lipoproteins -- LDL cholesterol -- Primary prevention; Cardiology -- Periodicals; Heart -- Diseases -- Periodicals; 616.12005
• DOI: 10.1093/eurheartj/ehac615
• Languages: English
• ISSNs: 0195-668X

Abstract

Abstract: Aims: Patients often require combination therapies to achieve LDL cholesterol (LDL-C) targets for the primary prevention of atherosclerotic cardiovascular disease. This study investigates the effect of inclisiran, a small interfering ribonucleic acid targeting hepatic proprotein convertase subtilisin/kexin type 9 production, in primary prevention patients with elevated LDL-C despite statins. Methods and results: This pre-specified analysis of the placebo-controlled, randomized ORION-11 trial included 203 individuals at risk of, but without prior, cardiovascular events and LDL-C ≥2.6 mmol/L, despite maximally tolerated statins. Inclisiran 284 mg or placebo was administered on Days 1, 90, and thereafter every 6 months up to 540 days. Co-primary endpoints were percentage LDL-C change from baseline to Day 510 and time-adjusted change from baseline after Day 90 and up to Day 540. Key secondary endpoints included percentage and absolute changes in atherogenic lipoproteins. Safety was assessed over 540 days. The mean baseline (SD) LDL-C was 3.6 (1.5) mmol/L. At Day 510, the placebo-corrected LDL-C change with inclisiran was −43.7% [95% confidence interval (CI): −52.8 to −34.6] with a corresponding time-adjusted change of −41.0% (95% CI: −47.8 to −34.2); ( P < 0.0001). The placebo-corrected absolute change in LDL-C at Day 510 with inclisiran was −1.5 mmol/L (95% CI: −1.8 to −1.2), with a respective time-adjusted change of −1.3 mmol/L (95% CI: −1.6 to −1.1). Inclisiran significantly lowered non-HDL cholesterol and apolipoprotein B (apoB) at Day 510 vs. placebo ( P < 0.0001 for both), with a greater likelihood of attaining lipoprotein and apoB goals, and was well-tolerated except for mainly mild, treatment-emergent adverse events at the injection site. Conclusion: Inclisiran was generally well-tolerated in primary prevention patients with elevated LDL-C, who derived significant reductions in atherogenic lipoprotein levels with twice-yearly maintenance dosing. Structured Graphical Abstract: Structured Graphical Abstract This pre-specified secondary analysis from the ORION-11 trial showed that inclisiran, an siRNA therapy targeting PCSK9 production, was generally well-tolerated in primary prevention patients with elevated LDL-C and resulted in significant reductions in atherogenic lipoprotein levels with twice-yearly maintenance dosing. ApoB, apolipoprotein B; CV, cardiovascular; DNA, deoxyribonucleic acid; LDL-C, low-density lipoprotein cholesterol; mRNA, messenger ribonucleic acid; non-HDL-C, non-high-density lipoprotein cholesterol; PCSK9, proprotein convertase subtilisin/kexin type 9; RNA, ribonucleic acid; siRNA, small interfering ribonucleic acid.